Icon

Mektovi - (15 mg; Tablet)

Binimetinib Array BioPharma
15 mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
MEKTOVI is a kinase inhibitor indicated, in combination with Encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Yes
*** *********** ******* ** *** **, ****. ***** ********* ***** * ****-** ** *** **, ****. ** *** **, **** ******* ****** *** **** ** ***** ******** **** ************ ** * *******, ******** ** ******, *** **** ***** * ****-** ** *** **** *******. **** ***** * ****-** **** ** * ******* ******** ** *** **** *** *** *********. ** ****** **** ***** * **** *** ** *** **** *** **** ****** ****** ****** *** **, ****.
Mektovi Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
******* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
****** *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
**** *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** / ********* *** **, **** ******* **** *** ****** *** ****
****** *** / ********* *** **, **** ******* **** *** ****** *** ****
**** *** / ********* -**- ******* **** ***** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** *** ***** *** *********.
  2. *** *, **** : **** ******** ***** ***** *** ****-** ****** **** ******* ’***, ’***, *** ’*** *** ******** ** *** **, ****
  3. *** **, **** : ******* ******** ***** ** *** ****-** ****** **** ******* '***, '***, '***, '***, '***, *** '***
  4. *** **, **** : ****** ******** ***** ***** *** ****-** ****** **** ******* '***, '***, '***, '***, '***, *** '***
  5. *** **, **** : ***** **** ******* **** ************ ** ******* '***, '***, '***, '***, '***, *** '***
  6. *** *, **** : ***** **** ****** **** ************ ** ******* '***, '***, '***, '***, '***, *** '***
  7. *** *, **** : ***** **** **** **** ************ ** ******* ’***, ’***, *** ’***

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.